San Diego/USA, 23 May 2006 – Patients with chronic obstructive pulmonary disease (COPD) treated with Spiriva® (tiotropium) for 6-12 months experienced significantly fewer exacerbations and hospitalisations compared with patients receiving placebo according to an analysis of pooled studies presented today at the International Conference of the American Thoracic Society (ATS).1 Spiriva® is the first and only once-daily, inhaled anticholinergic medication for maintenance treatment of COPD.
